Valiant Laboratories Limited (NSE:VALIANTLAB)

Market Cap	6.95B +52.5%
Revenue (ttm)	3.06B +89.6%
Net Income	160.14M +12,314.1%
EPS	2.95 +9,817.7%
Shares Out	54.31M
PE Ratio	43.38
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	235,078
Open	118.56
Previous Close	124.80
Day's Range	118.56 - 129.90
52-Week Range	49.51 - 129.90
Beta	1.04
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 12, 2026

About Valiant Laboratories

Valiant Laboratories Limited operates as an active pharmaceutical ingredient/bulk drug manufacturing company in India and internationally. The company manufactures paracetamol in various grades, such as Indian/British/European/the United States pharmacopoeias for the treatment of headaches, muscle aches, arthritis, back aches, toothaches, cold, and fever. It also offers specialty chemicals. The company was formerly known as Bharat Chemicals and changed its name to Valiant Laboratories Limited in August 2021. The company was founded in 1980 and ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1980
• Employees: 84
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: VALIANTLAB

Financial Performance

In fiscal year 2026, Valiant Laboratories's revenue was 2.37 billion, an increase of 78.04% compared to the previous year's 1.33 billion. Losses were -32.68 million, 48.5% more than in 2025.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 11, 2026

Data Sources Report a data error